Clinical Trials

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00092534 2025-08-01

FUTURE II

12,167 enrolled 23 charts

Phase 3 Active not recruiting

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT05056402 2025-07-22

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

1,382 enrolled

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT06681636 2024-11-08

HPV9vxFSW

300 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Recruiting

8,000 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT04895020 2024-04-17

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Phase 3 Recruiting

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Phase 3 Recruiting

1,348 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05584332 2023-07-21

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Terminated

3,131 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT04782895 2023-06-15

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

488 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT03900572 2023-04-13

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

90 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

GastrointestinalGynecologic

780 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

GastrointestinalGynecologic

160 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05580341 2022-10-28

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Phase 3 Unknown

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT04425291 2022-02-25

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

1,680 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT04905030 2021-06-11

Education, Immigration and HPV Vaccination: an Informational Randomized Trial

Phase NA Unknown

2,500 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Head and Neck Neoplasms, Penile Neoplasms, Vulvar Neoplasms

NCT03813940 2021-04-08

Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

24 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT03935204 2021-04-08

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

627 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT03546842 2020-02-25

V503-017

201 enrolled 11 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT03676101 2020-01-22

Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

90 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

1,212 enrolled 15 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00543543 2018-11-27

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

14,840 enrolled 21 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01047345 2018-11-27

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

924 enrolled 16 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

250 enrolled 20 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

3,882 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

1,877 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT02558803 2016-05-25

HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3

Phase NA Completed

1,305 enrolled

GynecologicHead & Neck

Uterine Cervical Neoplasms, Condylomata Acuminata, Oropharyngeal Neoplasms

NCT02551887 2016-03-11

HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts

Phase NA Completed

647 enrolled 7 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Condylomata Acuminata, Oropharyngeal Neoplasms

NCT00851643 2016-02-03

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

158 enrolled 12 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT00520598 2015-11-26

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

511 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00092521 2015-09-25

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

5,759 enrolled 10 charts

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00365443 2015-06-19

Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

620 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00501137 2015-04-10

BCGov-01

830 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00092495 2015-01-13

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

3,055 enrolled 25 charts

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00862810 2014-11-20

ADS

Phase 4 Completed

72 enrolled 5 charts